Natixis Advisors LLC Makes New $1.53 Million Investment in Insmed Incorporated (NASDAQ:INSM)

Natixis Advisors LLC bought a new stake in Insmed Incorporated (NASDAQ:INSM) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 20,894 shares of the biopharmaceutical company’s stock, valued at approximately $1,525,000.

Several other large investors have also made changes to their positions in INSM. Nisa Investment Advisors LLC boosted its position in Insmed by 8.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 135 shares in the last quarter. CIBC Asset Management Inc boosted its holdings in shares of Insmed by 3.5% in the 3rd quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 149 shares in the last quarter. CWM LLC grew its position in Insmed by 11.0% during the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 155 shares during the last quarter. GAMMA Investing LLC increased its holdings in Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares in the last quarter. Finally, First Horizon Advisors Inc. raised its position in Insmed by 83.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 287 shares during the last quarter.

Analysts Set New Price Targets

INSM has been the topic of several research analyst reports. JPMorgan Chase & Co. increased their target price on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday. TD Cowen increased their price objective on shares of Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Truist Financial restated a “buy” rating and issued a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Insmed in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $83.67.

Insmed Trading Up 1.3 %

NASDAQ INSM opened at $74.09 on Tuesday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The company has a market capitalization of $13.25 billion, a PE ratio of -13.18 and a beta of 1.12. The stock has a 50-day simple moving average of $72.04 and a 200 day simple moving average of $66.60.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. Insmed’s revenue for the quarter was up 18.1% compared to the same quarter last year. During the same quarter last year, the company earned ($1.10) EPS. Research analysts forecast that Insmed Incorporated will post -5.42 EPS for the current year.

Insider Transactions at Insmed

In other Insmed news, insider Michael Alexander Smith sold 27,871 shares of Insmed stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the transaction, the insider now owns 67,856 shares of the company’s stock, valued at approximately $5,045,093.60. The trade was a 29.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the sale, the insider now directly owns 100,100 shares of the company’s stock, valued at $7,157,150. This represents a 27.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 78,882 shares of company stock valued at $5,765,446 over the last three months. 4.60% of the stock is currently owned by corporate insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.